NMN and VO2 Max: Aerobic Capacity Evidence

NMN VO2 Max is one of the most searched intersections in longevity and performance science right now. For athletes and aging adults alike, aerobic capacity—the body's ability to take in, transport, and use oxygen during sustained exercise—serves as a powerful predictor of healthspan and functional independence. The question is whether nicotinamide mononucleotide (NMN), a direct precursor to the essential coenzyme NAD+, can meaningfully move that needle.

What the Research Actually Shows

The human evidence for NMN and VO2 Max is still emerging, but it is no longer purely theoretical. A small cluster of randomized controlled trials (RCTs) in humans provides the most relevant data, and the signal is strongest in trained individuals rather than sedentary populations.

The standout study comes from Liao et al. (2021), who conducted a randomized, double-blind, placebo-controlled trial in amateur runners. Participants received NMN at doses of 300 mg, 600 mg, or 1200 mg daily for six weeks. The researchers measured VO2 Max, along with other endurance markers, and found that NMN supplementation enhanced aerobic capacity in a dose-dependent manner. The 1200 mg group showed the largest gains, though even the 300 mg group demonstrated measurable improvements compared with placebo. This remains the only peer-reviewed RCT to date that has tested VO2 Max as a primary outcome with NMN.

Other human trials support NMN's physiological relevance but do not isolate VO2 Max. Igarashi et al. (2022) supplemented healthy older men with 250 mg NMN daily for 12 weeks and reported alterations in muscle function, including improved gait speed and grip strength. Yoshino et al. (2021) showed that NMN increased muscle insulin sensitivity in prediabetic women using 250 mg daily for 10 weeks. Neither study measured maximal oxygen uptake directly, but both demonstrate that NMN can influence muscle metabolism and performance capacity in ways that plausibly underpin aerobic gains.

Irie et al. (2020) provided early safety and pharmacokinetic data in healthy Japanese men, showing that oral NMN is well tolerated at up to 500 mg and reliably elevates blood NAD+ metabolites. Niu et al. (2023) explored broader metabolic and aging biomarkers in a pre-aging cohort, adding to the safety profile but not directly addressing exercise performance. The mechanistic foundation, meanwhile, traces back to Gomes et al. (2013), who demonstrated in animal models that declining NAD+ disrupts nuclear-mitochondrial communication and induces a pseudohypoxic state—one of the key cellular deficits that NMN is hypothesized to reverse.

Study	Population	Dose & Duration	VO2 Max Outcome	Key Limitations
Liao et al. (2021)	Amateur runners (n=48)	300–1200 mg/day, 6 weeks	Dose-dependent improvement	Small sample; no elite athletes
Igarashi et al. (2022)	Healthy older men (n=42)	250 mg/day, 12 weeks	Not measured	Muscle function only; no exercise testing
Yoshino et al. (2021)	Prediabetic women (n=25)	250 mg/day, 10 weeks	Not measured	Insulin sensitivity focus; small sample
Irie et al. (2020)	Healthy men (n=10)	Up to 500 mg/day, 5 weeks	Not measured	Safety/pharmacokinetic focus only
Niu et al. (2023)	Pre-aging adults (n=8)	300 mg/day, 8 weeks	Not measured	Very small sample; metabolic biomarkers only

The Mechanism: NAD+, Mitochondria, and Oxygen Utilization

VO2 Max is not a single organ's responsibility. It reflects the integrated function of the lungs, heart, blood, and muscle mitochondria. NMN enters this cascade at the cellular level by restoring NAD+, a coenzyme that declines with age and is indispensable for mitochondrial energy production.

Inside muscle cells, NAD+ serves as an electron shuttle for oxidative phosphorylation—the process by which mitochondria generate ATP using oxygen. When NAD+ levels drop, mitochondrial efficiency falls, and cells shift toward less efficient anaerobic pathways. Gomes et al. (2013) showed that this decline also disrupts the communication between the nucleus and mitochondria, creating a state of pseudohypoxia: the cell behaves as if oxygen is scarce even when it is not. This directly impairs the muscle's ability to sustain aerobic output.

NMN is structurally one step away from NAD+. Oral NMN is absorbed and converted to NAD+ in tissues including skeletal muscle. By replenishing this pool, NMN may restore mitochondrial oxidative capacity, improve the NAD+/NADH ratio, and support the sustained ATP production required during high-intensity aerobic exercise. This mechanism is consistent with the endurance improvements observed by Liao et al. (2021), though direct mechanistic confirmation in exercising humans remains limited.

It is worth noting that NMN is not a vasodilator or a hemoglobin modifier. It does not increase oxygen delivery the way altitude training or erythropoietin does. Its proposed benefit lies in oxygen utilization—how efficiently muscle mitochondria convert available oxygen into usable energy. That distinction matters when setting expectations.

Dosing, Form, and What We Still Don't Know

The effective dose in the Liao et al. (2021) trial ranged from 300 mg to 1200 mg daily, with higher doses producing larger effects. Most other human studies have used 250–500 mg. There is no established minimum effective dose for VO2 Max specifically, and no long-term data beyond 12 weeks.

Bio:sudo NMN 1000mg provides a dose that falls within the range associated with measurable aerobic improvements in the only available performance trial. For individuals already training consistently, this aligns with the dosing spectrum tested in the literature.

Several gaps remain unresolved. No study has tested NMN in elite endurance athletes, so whether benefits plateau or persist at higher fitness levels is unknown. There is no head-to-head comparison of NMN against other NAD+ precursors such as nicotinamide riboside (NR). And no published trial has combined NMN with structured training protocols to isolate whether the supplement adds to, or merely parallels, the adaptations produced by exercise itself.

NMN's effects on VO2 Max may also be population-specific. Older adults with lower baseline NAD+ could theoretically see larger relative gains than young, trained individuals whose NAD+ pools are already closer to optimal. The current evidence does not yet allow a firm conclusion on this point.

Who Benefits Most

The evidence profile suggests that NMN supplementation is most relevant for two overlapping groups: aging adults seeking to preserve aerobic capacity, and amateur endurance athletes looking for marginal gains.

For older adults, the rationale is preventive. VO2 Max declines by approximately 10% per decade after age 30, accelerating after 60. Since NAD+ also declines with age, restoring it may help slow this trajectory. Igarashi et al. (2022) and Yoshino et al. (2021) both worked with middle-aged or older populations and found metabolic and functional improvements, even if VO2 Max was not directly tested. For this group, NMN may function more as a metabolic maintenance tool than a performance enhancer.

For amateur runners and cyclists, the Liao et al. (2021) data offer the most direct support. These were not elite athletes—they were healthy individuals with regular training habits who saw measurable improvements in aerobic capacity after six weeks. The implication is that NMN may provide a small but real additive effect for those already near their training ceiling, where marginal gains are hardest to achieve.

Less compelling evidence exists for sedentary individuals seeking a shortcut. NMN is unlikely to substitute for training. Its mechanism depends on mitochondrial function, and mitochondria respond most robustly to the stimulus of exercise itself. For more on how NMN interacts with endurance training, see our deeper look at NMN for Endurance Athletes.

Practical Takeaways

• One RCT directly links NMN to improved VO2 Max. Liao et al. (2021) found dose-dependent aerobic gains in amateur runners over six weeks. This is the strongest evidence currently available.
• Higher doses appear more effective. The 1200 mg arm outperformed 300 mg and 600 mg in that trial, though even the lowest dose showed benefit.
• NMN works at the mitochondrial level. It does not increase oxygen delivery; it may improve how efficiently muscle cells use the oxygen already available.
• Aging populations have the strongest mechanistic rationale. Declining NAD+ and declining VO2 Max track together with age, and early trials in older adults show functional improvements.
• Do not expect NMN to replace training. The supplement appears to augment adaptations in already-active individuals, not create them from zero.
• Safety data are reassuring but short-term. Human trials up to 12 weeks report good tolerability, with no serious adverse events at doses up to 1200 mg daily.

Bottom Line

The evidence for NMN VO2 Max benefits is promising but narrow. A single well-designed RCT in amateur runners supports a genuine, dose-dependent effect on aerobic capacity, while other human studies confirm metabolic activity and safety without directly testing maximal oxygen uptake. NMN is best viewed as a mitochondrial support tool with potential endurance applications—not a standalone performance enhancer. For those interested in the cellular mechanisms behind these effects, our article on NMN and Mitochondria explores the NAD+ pathway in more detail, and our guide to NMN for Energy covers the broader metabolic implications.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---